Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTA-rosopatamab in PSMA-positive mCRPC
NCT04876651Phase 3Terminated
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of 177lu-rosopatamab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Telix Pharmaceuticals Limited. Primary endpoint: Radiographic Progression-Free Survival at 5 years. Started Aug 2023; status: terminated.
02
Drugs
177lu-rosopatamab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04876651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04876651.